Q3 2024 Bactiguard Holding AB Earnings Call Transcript
Welcome to the presentation of Bactiguard Q3 2024 report. I will go through the presentation together with my colleague, Patrick Bach, our co and open up for questions towards the end. Thank you all for dialing in today.
Let's go straight into the overarching theme of the report. We are very pleased to announce profitability on an EBITA level both for the third quarter and year-to-date. This is a demonstration that our license focused strategy and business model that we embarked on late last year is working and effective.
As you know, we also had some disappointing news in early October after the end of the quarter when Zimmer Biomet terminated the agreement covering multiple orthopedic product segments.
The broad commercial potential in these segments was a key driver of our 2028 financial targets, considering this and to further take the opportunity for reflection after last year's transformation work, we have decided to initiate a review of our financial targets. The outcome will be communicated in Q1 2025.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |